ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report Report documents ESG accomplishments and reflects commitment to corporate responsibility

ADC Therapeutics Releases its Inaugural Environmental,

Social and Governance Report

Report documents ESG accomplishments and reflects

commitment to corporate responsibility

LAUSANNE, Switzerland, February 17, 2022

- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with

its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today unveiled

its first Environmental, Social and Governance (ESG) report detailing the Company's focus on patient care and sustainable innovation.

The report marks a milestone in the Company's evolution and provides a benchmark for future progress.

"The team at ADC Therapeutics is dedicated

to transforming the lives of cancer patients while exemplifying transparent, ethical and responsible business practices," said Chris

Martin, DPhil, Chief Executive Officer of ADC Therapeutics. "Our first ESG report highlights our commitment to being good corporate

citizens in the communities we live and work in. Corporate responsibility goes hand in glove with our mission to create innovative global

healthcare solutions."

Highlights from the report include:

The Environmental, Social and Governance report

is available by clicking here or by visiting the Company's website: www.adctherapeutics.com.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage

biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The

Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies

ADC Therapeutics' CD19-directed ADC ZYNLONTA

(loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two

or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being

evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced

solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biop le),

Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/

and follow the Company on Twitter and LinkedIn.

ZYNLONTA is a registered trademark of ADC Therapeutics SA.

Tel.: +1 914-552-4625